Lundbeck-Takeda Drug Fights Depression Better at Higher Dose
This article is for subscribers only.
H. Lundbeck A/S, Denmark’s second-largest drugmaker, said its experimental antidepressant Brintellix improved symptoms better in a higher dose in a late-stage U.S. study, as the medicine awaits regulatory approval.
Brintellix, also known as vortioxetine, significantly improved symptoms in the 20-milligram dose, with patients’ scores on the Montgomery-Asberg Depression Rating Scale falling by 15.57 after 8 weeks of treatment, compared with 16.90 for patients taking 60 milligrams of Eli Lilly & Co.’s Cymbalta, Lundbeck and trial partner Takeda Pharmaceutical Co. said in a statement yesterday. The 15-milligram dose of Brintellix didn’t meet statistical significance, the companies said.